October 4 @ 11:00 AM – 11:30 AM
Join Matt Tremblay, Ph.D., CEO of Blackbird Laboratories, and Chris Frew, CEO of BioBuzz Networks LIVE on LinkedIn as they buzz about BlackBird’s mission to cultivate a vibrant entrepreneurial ecosystem in Baltimore.
Learn about:
– Early Stage and De-risking Technology: Explore strategies for nurturing early-stage innovations and reducing risks in emerging technologies.
– Strengthening the Baltimore and Maryland Biotech Ecosystem: Learn about efforts to unify the Baltimore life sciences community with the suburban Maryland biotech sector, creating a more integrated network.
– AI in Biotech: Hype vs. Hope: Delve into the realistic impact of AI in biotech, distinguishing between exaggerated claims and genuine advancements.
About Matt Tremblay
Matt Tremblay, PhD, is the Chief Executive Officer of Blackbird Laboratories, a nonprofit technology development platform, and Managing Director of Wolf Point, an early stage biotech investment fund. Blackbird and Wolf Point aim to catalyze the creation of new medicines and enabling technologies in Baltimore.
Prior to joining Blackbird, Tremblay was Chief Operating Officer of Scripps Research and its drug discovery division, Calibr. He earned his PhD in Chemistry at Columbia University. Following postdoctoral work in the laboratory of Peter Schultz, PhD, at Scripps Research, he led a group at the Genomics Institute of the Novartis Research Foundation until helping to launch and run Calibr for 10 years.